Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group.

Suppr

超能文献

作者信息

Porayko M K, Gonwa T A, Klintmalm G B, Wiesner R H

机构信息

Liver Transplant Unit, Mayo Clinic, Rochester, MN 55905.

出版信息

Transplant Proc. 1995 Feb;27(1):1114-6.

PMID:7533358

Abstract

摘要

相似文献

Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group.

Transplant Proc. 1995 Feb;27(1):1114-6.

Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients.

Transplant Proc. 1993 Feb;25(1 Pt 1):665-8.

Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group.

Transplant Proc. 1993 Feb;25(1 Pt 1):635-7.

Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group.

Transplant Proc. 1995 Feb;27(1):1121-3.

Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.

Transplant Proc. 1993 Feb;25(1 Pt 1):679-88.

FK 506 rescue therapy: early conversion improves efficacy.

Transplant Proc. 1993 Apr;25(2):1990-1.

Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.

Transplant Proc. 1995 Feb;27(1):45-9.

Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.

Transplant Proc. 1993 Apr;25(2):1988-9.

Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group.

Transplant Proc. 1995 Feb;27(1):1124.

FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.

Transplant Proc. 1993 Apr;25(2):1992-3.

引用本文的文献

Comparison of whole-blood tacrolimus concentrations measured by different immunoassay systems.

J Clin Lab Anal. 2018 Nov;32(9):e22587. doi: 10.1002/jcla.22587. Epub 2018 Jul 5.

Prophylaxis of chronic kidney disease after liver transplantation--experience from west China.

World J Gastroenterol. 2012 Mar 7;18(9):991-8. doi: 10.3748/wjg.v18.i9.991.

Evidence for the immunosuppressive potential of calcineurin inhibitor-sparing regimens in liver transplant recipients with impaired renal function.

J Transplant. 2011;2011:483728. doi: 10.1155/2011/483728. Epub 2011 Jul 6.

Immunosuppressive therapy in older cardiac transplant patients.

Drugs Aging. 2007;24(11):913-32. doi: 10.2165/00002512-200724110-00004.

Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events.

Liver Transpl Surg. 1999 Mar;5(2):144-50. doi: 10.1002/lt.500050209.

A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results.

J Thorac Cardiovasc Surg. 1996 Apr;111(4):764-72. doi: 10.1016/s0022-5223(96)70336-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验